J Menopausal Med.  2019 Apr;25(1):49-54. 10.6118/jmm.2019.25.1.49.

The Effects of Menopausal Hormone Therapy on Serum Level of C-reactive Protein in Postmenopausal Korean Women

Affiliations
  • 1Department of Obstetrics, Gynecology, and Women's Health, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. bkyoon@skku.edu

Abstract


OBJECTIVES
Inflammation is a major mechanism underlying coronary heart disease (CHD) and C-reactive protein (CRP) is a marker of inflammation. When administered soon after menopause, menopausal hormone therapy (MHT) prevents CHD. This study was conducted to examine the impact of estrogen by administration route on CRP in postmenopausal Korean women using micronized progesterone (MP4) for endometrial protection.
METHODS
This retrospective cohort study included 129 healthy women without CHD risk factors. Eighty-nine women took oral estrogen (conjugated equine estrogen, 0.625 mg/day or equivalent), and 40 women applied a 1.5-mg/day 0.1% percutaneous estradiol gel. MP4 was added in 82 women with an intact uterus. The CRP level was measured at baseline and three and six months after initiation of MHT.
RESULTS
The baseline characteristics were comparable between the MHT groups except current age and age at menopause. After controlling for age, menopausal age, body mass index, and basal CRP, no significant change in CRP was observed in the oral estrogen group (n = 29). Follow-up CRP levels were also similar to the baseline in the percutaneous estrogen group (n = 18). However, three-month CRP was significantly lower than six-month CRP, and there was a significant time trend within the percutaneous estrogen group. However, the group difference did not reach statistical significance. CRP also did not differ by addition of MP4 in either group.
CONCLUSIONS
In postmenopausal Korean women, no change in CRP was observed with oral estrogen, while percutaneous estrogen might decrease CRP. The estrogenic impacts were not influenced by adding MP4.

Keyword

C-reactive protein; Hormone replacement therapy; Progesterone; Postmenopause; Drug administration routes

MeSH Terms

Body Mass Index
C-Reactive Protein*
Cohort Studies
Coronary Disease
Drug Administration Routes
Estradiol
Estrogens
Female
Follow-Up Studies
Hormone Replacement Therapy
Humans
Inflammation
Menopause
Postmenopause
Progesterone
Retrospective Studies
Risk Factors
Uterus
C-Reactive Protein
Estradiol
Estrogens
Progesterone
Full Text Links
  • JMM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr